Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects 18 years or older~2. Diagnosis of multiple myeloma~3. Measurable, secretory multiple myeloma defined as serum monoclonal IgG of ≥10 g/L, serum monoclonal IgA or IgE ≥5 g/L, or serum monoclonal IgD ≥0.5g/L; or urine M-protein of ≥200 mg/24 hr~4. Relapse or progression of myeloma following prior systemic antineoplastic therapy.~Exclusion Criteria:~1. Previous treatment with VELCADE~2. More than 3 previous lines of therapy (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a greater than 6 month treatment-free interval)~3. Peripheral neuropathy or neuropathic pain of NCI CTCAE Grade ≥2~4. Any of the following within 3 weeks prior to randomization:~   antineoplastic or experimental therapy, corticosteroid use above 10mg a day (prednisone or equivalent), or plasmapheresis~5. Any of the following within 2 weeks prior to randomization:~   radiation therapy, major surgery (kyphoplasty is not considered major surgery)~6. Prior malignancy other than multiple myeloma diagnosed or treated within the last 2 years, with the exception of completely resected carcinoma in situ or basal/squamous carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): VELCADE administered by subcutaneous injection
- 2 (Type: ACTIVE_COMPARATOR): VELCADE administered by intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).